Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
While Ozempic mimics one hunger-relieving hormone, and Mounjaro mimics two, Eli Lilly is working on what's called a "triple agonist," with three different hormone-like substances inside.
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
BI Illustration Eli Lilly makes the popular shots Mounjaro and Zepbound. Next, the company says they have a pill coming that could be as powerful as rival Ozempic. The company's head of obesity said ...
The news has put pressure on Eli Lilly, whose shares fell as the market reacted to the potential challenge to its obesity drug, Zepbound, also known as Mounjaro. Despite earlier success ...
To address this, American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.